NasdaqGS - Nasdaq Real Time Price USD
Denali Therapeutics Inc. (DNLI)
As of 1:58 PM EDT. Market Open.
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
1,267.00
330,531.00
108,463.00
48,661.00
335,659.00
--
Operating Expense
496,479.00
527,230.00
449,207.00
344,412.00
272,941.00
--
Operating Income
-495,212.00
-196,699.00
-340,744.00
-295,751.00
62,718.00
--
Net Non Operating Interest Income Expense
61,051.00
51,505.00
14,774.00
4,595.00
9,241.00
--
Pretax Income
-419,624.00
-145,194.00
-325,970.00
-291,156.00
71,959.00
--
Tax Provision
--
30.00
21.00
-575.00
823.00
--
Net Income Common Stockholders
-419,654.00
-145,224.00
-325,991.00
-290,581.00
71,136.00
--
Diluted NI Available to Com Stockholders
-419,654.00
-145,224.00
-325,991.00
-290,581.00
71,136.00
--
Basic EPS
-2.86
-1.06
-2.60
-2.39
0.65
--
Diluted EPS
-2.86
-1.06
-2.60
-2.39
0.63
--
Basic Average Shares
148,536.12
137,370.90
125,530.70
121,524.80
108,974.14
--
Diluted Average Shares
148,536.12
137,370.90
125,530.70
121,524.80
112,703.11
--
Total Operating Income as Reported
-480,675.00
-196,699.00
-340,744.00
-295,751.00
62,718.00
--
Total Expenses
496,479.00
527,230.00
449,207.00
344,412.00
272,941.00
--
Net Income from Continuing & Discontinued Operation
-419,654.00
-145,224.00
-325,991.00
-290,581.00
71,136.00
--
Normalized Income
-434,191.00
-145,224.00
-325,991.00
-290,581.00
71,136.00
--
Interest Income
61,051.00
51,505.00
14,774.00
4,595.00
9,241.00
--
Net Interest Income
61,051.00
51,505.00
14,774.00
4,595.00
9,241.00
--
EBIT
-495,212.00
-196,699.00
-340,744.00
-295,751.00
62,718.00
--
EBITDA
-486,714.00
-179,973.00
-330,361.00
-287,158.00
71,249.00
--
Reconciled Depreciation
8,498.00
16,726.00
10,383.00
8,593.00
8,531.00
--
Net Income from Continuing Operation Net Minority Interest
-419,654.00
-145,224.00
-325,991.00
-290,581.00
71,136.00
--
Total Unusual Items Excluding Goodwill
14,537.00
--
--
--
--
--
Total Unusual Items
14,537.00
--
--
--
--
--
Normalized EBITDA
-501,251.00
-179,973.00
-330,361.00
-287,158.00
71,249.00
--
Tax Rate for Calcs
--
0.00
0.00
0.00
0.00
--
12/31/2019 - 12/8/2017
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
RARE Ultragenyx Pharmaceutical Inc.
54.66
+0.37%
ALEC Alector, Inc.
4.6900
+1.74%
DYN Dyne Therapeutics, Inc.
33.25
-0.70%
KYMR Kymera Therapeutics, Inc.
48.24
+3.61%
AGIO Agios Pharmaceuticals, Inc.
45.05
-1.34%
BPMC Blueprint Medicines Corporation
86.51
+1.05%
ANAB AnaptysBio, Inc.
35.34
-0.10%
RVMD Revolution Medicines, Inc.
46.85
-1.88%
NMRA Neumora Therapeutics, Inc.
14.00
-0.36%
AKRO Akero Therapeutics, Inc.
29.99
-2.94%